GLOW trial (NCT03653507): The efficacy of zolbetuximab was evaluated in a global phase III trial, GLOW, which used capecitabine and oxaliplatin (CAPOX) as a first line treatment for CLDN18.2-positive, HER2-negative, locally advanced unresectable GC/GEJ adenocarcinoma. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.